Royer Biomedical, Inc.

RBI completes European distribution agreement

Laura — Wed, 25 Jul 2012 19:22:41 +0000

RBI is pleased to announce completion of a European distribution agreement with Equus MedicLine Europe bvba, a division of Equus Sport Europe, for distribution of VetriGel and other RBI veterinary products.;

RBI receives FDA approval to proceed with Human Testing (IND 111446) for its AppliGel Polymer Drug Delivery System

Laura — Wed, 06 Jun 2012 20:51:56 +0000

FREDERICK, Md.–(BUSINESS WIRE)–Royer Biomedical, Inc. (RBI) received FDA approval to proceed with Human Testing of AppliGel-G (Gentamicin) in management of Diabetic Foot Ulcers (DFU). AppliGel is a patented proprietary dissolvable non-immunogenic Polymer Drug Delivery System Platform. It has demonstrated efficacy in biofilm and infection eradication, without significant systemic API levels.

“This represents an important milestone in the development of AppliGel,” said William Wolf, MD, RBI’s President and CEO. “We are excited at the prospect of helping diabetics and their Physicians in the management of this difficult and limb-threatening disorder. We look forward to gaining final approval for topical, injectable, and implantable drug delivery applications for antibiotics, chemotherapeutics, and analgesics to address DFU, Cancers, and other conditions requiring sustained medication in a dissolvable platform without immunogenic reaction or the need for removal. Our AppliGel polymer platform’s shelf stability, ease of application, and ability to deliver pharmaceuticals without significant adverse effects has been well-demonstrated in the veterinary world, and the prospect of collaborating with Johns Hopkins University Hospital and Georgetown University Hospital to improve patient outcomes in Cancer and Diabetes is truly exciting.”

Contacts

Royer Biomedical, Inc.
William Wolf, MD, President and CEO, 301-696-2177
office@royerbiomedical.com

Royer Biomedical, Inc. Awarded US Patent for its AppliGel Polymer Drug Delivery System

Laura — Mon, 19 Dec 2011 21:53:27 +0000

FREDERICK, Md.–(BUSINESS WIRE)—Royer Biomedical Inc. (RBI) was awarded a US patent covering the core technologies of its proprietary AppliGel dissolvable non-immunogenic Polymer Drug Delivery System Platform. The US Patent and Trademark Office allowed 53 claims broadly covering composition of matter, methods, commercial kits, and formulations. AppliGel Drug Delivery System Platform received pre-IND pathway concurrence earlier this year. The Company is nearing completion of required animal testing in anticipation of submission to the FDA for an IND to initiate Phase I/II human testing in Q2 of 2012.

“This patent represents years of innovation and development” said William Wolf MD, RBI’s President and CEO. “We are proud that the USPTO has allowed such a broad set of claims, and we look forward to gaining final approval for topical, injectable, and implantable drug delivery applications for antibiotics, chemotherapeutics, and analgesics to address Diabetic Foot Ulcers (DFU), Oncology, and other conditions requiring sustained medication in a dissolvable platform without immunogenic reaction or the need for removal. Our AppliGel polymer platform’s shelf stability, ease of application, and ability to deliver pharmaceuticals without significant adverse effects has been well-demonstrated in the veterinary world, and the prospect of collaborating with Johns Hopkins University Hospital and Georgetown University Hospital to improve patient outcomes in Cancer and Diabetes is truly exciting.”